High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment

被引:65
|
作者
Naik, Biswajit [1 ]
Gupta, Nidhi [1 ]
Ojha, Rupal [1 ]
Singh, Satyendra [1 ]
Prajapati, Vijay Kumar [1 ]
Prusty, Dhaneswar [1 ]
机构
[1] Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH-8, Ajmer 305817, Rajasthan, India
关键词
COVID-19; Natural compounds; Muti-target; Molecular docking; Molecular dynamics; MOLECULAR DOCKING; SARS CORONAVIRUS; STRUCTURE VALIDATION; ANTIOXIDANT ACTIVITY; POTENT INHIBITORS; CRYSTAL-STRUCTURE; VIRUS ACTIVITY; DRUG TARGETS; EBOLA-VIRUS; RNA VIRUS;
D O I
10.1016/j.ijbiomac.2020.05.184
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti-SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 50 条
  • [21] Monoclonal antibody therapy in COVID-19 induced by SARS-CoV-2
    Conti, P.
    Pregliasco, F. E.
    Calvisi, V.
    Caraffa, A.
    Gallenga, C. E.
    Kritas, S. K.
    Ronconi, G.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021, 35 (02): : 423 - 427
  • [22] Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
    Hwang, Yu-Chyi
    Lu, Ruei-Min
    Su, Shih-Chieh
    Chiang, Pao-Yin
    Ko, Shih-Han
    Ke, Feng-Yi
    Liang, Kang-Hao
    Hsieh, Tzung-Yang
    Wu, Han-Chung
    JOURNAL OF BIOMEDICAL SCIENCE, 2022, 29 (01)
  • [23] Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)
    Verma, Surjeet
    Twilley, Danielle
    Esmear, Tenille
    Oosthuizen, Carel B.
    Reid, Anna-Mari
    Nel, Marize
    Lall, Namrita
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [24] Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
    Yu-Chyi Hwang
    Ruei-Min Lu
    Shih-Chieh Su
    Pao-Yin Chiang
    Shih-Han Ko
    Feng-Yi Ke
    Kang-Hao Liang
    Tzung-Yang Hsieh
    Han-Chung Wu
    Journal of Biomedical Science, 29
  • [25] In Silico Multi-Target Approach Revealed Potential Lead Compounds as Scaffold for the Synthesis of Chemical Analogues Targeting SARS-CoV-2
    Trezza, Alfonso
    Mugnaini, Claudia
    Corelli, Federico
    Santucci, Annalisa
    Spiga, Ottavia
    BIOLOGY-BASEL, 2022, 11 (03):
  • [26] Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?
    Wright C.
    Ross C.
    Mc Goldrick N.
    Evidence-Based Dentistry, 2020, 21 (2) : 64 - 65
  • [27] Early Outpatient Treatment of SARS-CoV-2 (COVID-19): A Comment
    Korman, Tony M.
    McMahon, James H.
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (03): : E220 - E221
  • [28] Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
    Li, Yang
    Lu, Si-Ming
    Wang, Jia-Long
    Yao, Hang-Ping
    Liang, Li Guo
    HELIYON, 2024, 10 (12)
  • [29] Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19
    Faheem
    Kumar, Banoth Karan
    Sekhar, Kondapalli Venkata Gowri Chandra
    Kunjiappan, Selvaraj
    Jamalis, Joazaizulfazli
    Balana-Fouce, Rafael
    Tekwani, Babu L.
    Sankaranarayanan, Murugesan
    BIOORGANIC CHEMISTRY, 2020, 104
  • [30] Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
    Pastick, Katelyn A.
    Okafor, Elizabeth C.
    Wang, Fan
    Lofgren, Sarah M.
    Skipper, Caleb P.
    Nicol, Melanie R.
    Pullen, Matthew F.
    Rajasingham, Radha
    McDonald, Emily G.
    Lee, Todd C.
    Schwartz, Ilan S.
    Kelly, Lauren E.
    Lother, Sylvain A.
    Mitja, Oriol
    Letang, Emili
    Abassi, Mahsa
    Boulware, David R.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (04):